Drug patents …
… from Kazakhstan to Kalamazoo
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Anticipate generic drug launch
Find generic entry opportunities
Manage your formulary budget
Proactively manage your pharmacy inventory
|Title:||High-affinity oligonucleotide ligands to immunoglobulin E (IgE)|
|Abstract:||This invention discloses high-affinity oligonucleotide ligands to human Immunoglobulin E (IgE), specifically RNA ligands having the ability to bind to IgE, and the methods for obtaining such ligands. The ligands are capable of inhibiting the interaction of IgE with its receptor.|
|Inventor(s):||Wiegand; Torsten W. (Boulder, CO), Tasset; Diane (Boulder, CO), Gold; Larry (Boulder, CO)|
|Assignee:||NeXstar Pharmaceuticals, Inc. (Boulder, CO)|
|Filing Date:||Oct 03, 1994|
|Claims:||1. A method for identifying nucleic acid ligands to Immunoglobulin E (IgE), comprising: |
a) preparing a candidate mixture of nucleic acids;
b) contacting said candidate mixture of nucleic acids with IgE, wherein nucleic acids having an increased affinity to the IgE relative to the candidate mixture may be partitioned from the remainder of the candidate mixture;
c) partitioning the increased affinity nucleic acids from the remainder of the candidate mixture; and
d) amplifying the increased affinity nucleic acids to yield a mixture of nucleic acids enriched for nucleic acid sequences with relatively higher affinity and specificity for binding to IgE, whereby nucleic acid ligands of IgE may be identified.
2. The method of claim 1 further comprising:
e) repeating steps b), c) and d).
3. The method of claim 1 wherein said candidate mixture is comprised of single-stranded nucleic acids.
4. The method of claim 3 wherein said single-stranded nucleic acids are ribonucleic acids.
5. The method of claim 3 wherein said single-stranded nucleic acids are deoxyribonucleic acids.